The report on Moderna was published on April 11, 2026. Share the report or generate your own report on Finsight Alpha.
Moderna
Bearish/NeutralExecutive Summary
Moderna's recent financial performance raises significant concerns for investors, particularly regarding its reliance on COVID-19 vaccine revenues. The company's revenue plummeted from $3.20 billion in 2024 to $1.94 billion in 2025, highlighting a troubling trend that questions the sustainability of its growth. Coupled with an operating cash flow of -$1.87 billion, these figures suggest that Moderna faces substantial challenges in generating cash and maintaining operational viability.
Moreover, the biotechnology sector's competitive landscape complicates Moderna's prospects. As demand for its COVID-19 vaccine wanes, the company must diversify its offerings to mitigate risks associated with its current revenue model. Intense competition from established players like Pfizer and BioNTech further exacerbates these challenges, making it imperative for Moderna to successfully launch new products and expand into international markets. The negative earnings yield of -14.13% and absence of dividends may deter potential investors, signaling a lack of confidence in future returns.
In summary, Moderna's heavy reliance on a declining revenue stream and its ongoing cash generation difficulties present significant risks that overshadow any potential for recovery. Investors should approach with caution, as the company's ability to pivot and diversify remains uncertain. The outlook is decidedly Bearish/Neutral.
Next reported earnings: Thursday, 7 May 2026, before market open.
Key Metrics
| Market Cap | $20.13 B | |
| 6-Month Share Price Change | 89.94% | |
| Revenue (TTM) | $1.94 B | |
| EBITDA (TTM) | ($2.55 B) | |
| EPS (TTM) | ($7.20) | |
| Operating Cash Flow (TTM) | ($1.84 B) | |
| Free Cash Flow (TTM) | ($2.04 B) | |
| Cash and cash equivalents | $2.60 B | |
| P/E Ratio (TTM) | (7.08) | |
| Price/Book (TTM) | 2.31 | |
| Debt/Equity | 0.22 | |
| Current Ratio | 3.29 | |
| Dividend Yield (TTM) | No data |
Tap or click the i icon for a metric definition.
The Moderna Story
Founded in 2010 and headquartered in Cambridge, Massachusetts, Moderna has emerged as a leader in the biotechnology sector, focusing on messenger RNA (mRNA) technology to develop vaccines and therapeutics. The company's breakthrough came with the rapid development of its COVID-19 vaccine, which received emergency use authorization in December 2020. This milestone not only validated its innovative approach but also propelled Moderna into the global spotlight.
Moderna's business model revolves around leveraging its mRNA platform to create a pipeline of vaccines and treatments for various diseases. Following the success of its COVID-19 vaccine, the company has expanded its research efforts into other infectious diseases, cancer, and rare genetic disorders. However, the reliance on a single product poses risks, as the pandemic-driven demand may not sustain long-term growth. Taken together, Moderna's ability to pivot and diversify its offerings will be crucial for its future in an increasingly competitive landscape.
Macro Industry Position
Biotechnology addresses critical healthcare challenges by developing innovative therapies and vaccines that improve patient outcomes. Within the healthcare sector, the biotechnology industry has gained prominence, driven by advancements in genetic research and technology. Key players include Pfizer and BioNTech, both of which have made significant strides in vaccine development. Additionally, companies in the pharmaceutical sector, such as Gilead Sciences, serve as substitutes by offering alternative treatments for various diseases, highlighting the competitive dynamics at play.
The competitive landscape in biotechnology is defined by rapid innovation and the race to develop effective therapies. Companies compete on the basis of research and development capabilities, speed to market, and regulatory approval processes. Moderna has positioned itself as a leader in mRNA technology, leveraging its platform to create a diverse pipeline of vaccines and therapeutics. However, its heavy reliance on the success of its COVID-19 vaccine raises concerns about long-term sustainability, especially as pandemic-related demand wanes.
Margin pressures in the biotechnology sector stem from rising employment costs, increased regulatory scrutiny, and the need for substantial investment in research and development. As consumer prices rise, companies face challenges in maintaining profitability while navigating reimbursement pressures from payers. Additionally, fluctuations in the cost of capital can impact funding for ongoing projects, making it essential for firms like Moderna to manage their financial strategies effectively in this evolving macro environment.
Moderna operates in a challenging macroeconomic environment, particularly when comparing the US to the Euro-area. While US inflation sits at 3.3 % year over year, Euro-area inflation is significantly lower at 1.9 %. This disparity suggests that Moderna may face higher operational costs in the US, impacting its pricing strategies and profit margins. The ECB deposit rate remains at 2.00 %, which contrasts with the Fed-funds rate of 3.64 %, indicating tighter monetary conditions in the US. Such differences could affect Moderna's ability to secure favorable financing for research and development initiatives. Additionally, the US 10-year yield stands at 4.29 %, unchanged, while the Euro 10-year yield is slightly lower at 3.22 %. These factors collectively shape the financial landscape in which Moderna must operate, influencing its investment decisions and overall market positioning.
Bottom line: Moderna's leadership in mRNA technology faces significant pressures from both industry dynamics and macroeconomic factors. The reliance on COVID-19 vaccine revenues raises sustainability concerns amid declining demand. Coupled with rising employment costs and reimbursement pressures, the company must navigate a complex financial environment characterized by higher inflation and interest rates. As Moderna seeks to diversify its pipeline, the interplay between these macroeconomic indicators and its operational strategies will be critical for maintaining profitability and growth in the coming years.
Recent Developments
On April 6, 2026, Moderna announced plans to present late-breaking oral presentations on revaccination data for its investigational seasonal influenza vaccine, mRNA-1010, and its mRNA respiratory syncytial virus vaccine, mRESVIA, at the 2026 European Society of Clinical Microbiology and Infectious Diseases Global Congress in Munich, Germany, scheduled for April 17-21, 2026. The presentation titled "Sequential administration of an mRNA-based seasonal influenza vaccine in older adults" focused on an exploratory, post-hoc analysis assessing the safety and immunogenicity of mRNA-1010 in adults aged 50 years and older following prior seasonal influenza vaccination with either mRNA-1010 or a licensed egg-based influenza vaccine [1].
On April 8, 2026, Bank of America highlighted international opportunities as a key growth driver for Moderna. Analysts noted that the 2025-2026 vaccine season was winding down and that the company's litigation risks were largely in the past after a $950 million upfront payment in the first quarter. They also mentioned the potential for up to $1.3 billion in additional payments depending on the outcome of an ongoing legal appeal [2][3].
On April 9, 2026, Moderna's stock closed at $51.3, reflecting a decline of 1.54% from the previous day, despite improvements in the broader market [4]. This decline occurred amid ongoing discussions about the company's performance and future prospects, particularly in light of its recent announcements and market conditions.
For investors, these updates indicate a focus on expanding Moderna's portfolio beyond COVID-19 vaccines, particularly through international markets and new vaccine developments. The company's financial position remains strong, with significant cash reserves, but the recent stock decline may raise concerns about its market performance and revenue generation capabilities in the near term [5].
Sources
- [1] Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026 (Apr 6, 2026)
- [2] Bank of America flags international opportunities as key growth driver for Moderna (Apr 8, 2026)
- [3] Moderna eyes international markets as growth driver, says Bank of America (Apr 8, 2026)
- [4] Moderna (MRNA) Stock Declines While Market Improves: Some Information for Investors (Apr 9, 2026)
- [5] Moderna: Speculative Buy For Aggressive Investors Betting On mRNA's Future (Apr 6, 2026)
Financial Deep-Dive
Welcome to the Financial Deep-Dive. The eight tabs below organise Moderna's financial data into valuation, profitability, per-share data, leverage, liquidity, efficiency, working-capital, and R&D. Each tab presents financial metrics and trend charts for its category, along with key strengths and weaknesses. Click on any measure for a clear definition and insight into its relevance for investors. At the bottom, you'll find a detailed Financial Health Summary outlining Moderna's financial condition based on their most recent accounts.
Financial Health Summary
For the fiscal year 2025, Moderna reported revenue of $1.94 billion, a decline from $3.20 billion in fiscal year 2024. In the latest quarter, the company generated revenue of $0.68 billion, with an EBITDA of -$0.73 billion. Over the trailing twelve months, operating cash flow stood at -$1.87 billion, indicating ongoing challenges in cash generation.
Moderna's market capitalization is currently $20.13 billion, with a price-to-earnings ratio of -7.08 and an enterprise-value-to-EBITDA multiple of -7.62. These figures reflect a market that is pricing in significant uncertainty regarding profitability. The company's liquidity appears strong, with cash and cash equivalents totaling $2.60 billion and a current ratio of 3.29, suggesting it can cover short-term obligations. However, the negative earnings yield of -14.13% and a payout ratio of 0.00% indicate that shareholders are not currently receiving dividends, which may raise concerns about future returns.
Moderna faces notable risks, particularly in cash generation, as operating cash flow per share decreased over the reporting period, signaling pressure on its ability to generate cash from operations. The cash conversion cycle improved, reflecting fewer days tied up in working capital, while days of inventory outstanding also decreased, indicating better inventory management. However, days of payables outstanding increased, suggesting that the company is taking longer to pay suppliers, which could impact relationships and future supply chain dynamics.
Verdict: Moderna's financial health is characterized by significant cash flow challenges and declining revenues, despite a solid liquidity position. The company must navigate these risks carefully to restore investor confidence and improve its operational efficiency.
Risks and Concerns
Moderna's heavy reliance on COVID-19 vaccine revenues poses a significant operational risk. In fiscal year 2025, the company reported revenue of $1.94 billion, a sharp decline from $3.20 billion in 2024. As pandemic-related demand wanes, the sustainability of this revenue stream is in question, raising concerns about the company's ability to maintain growth without successful diversification into other markets or products.
Market dynamics further complicate Moderna's position. The biotechnology sector is characterized by intense competition, with key players like Pfizer and BioNTech advancing their own vaccine developments. As these competitors innovate, Moderna must not only keep pace but also expand its pipeline beyond COVID-19. Any setbacks in launching new vaccines or entering international markets could significantly weaken investor confidence and hinder potential revenue growth.
Financially, Moderna faces challenges that could impact shareholder returns. The company reported an operating cash flow of -$1.87 billion, indicating ongoing difficulties in cash generation. With a negative earnings yield of -14.13% and no dividends currently being paid, investors may question the viability of their investment. As Moderna navigates these financial pressures, its ability to restore profitability and investor trust will be crucial for long-term success.
Outlook
Moderna's future hinges on its ability to diversify beyond COVID-19 vaccine revenues, which have been the cornerstone of its financial success. As demand for these vaccines declines, the company must pivot effectively to new markets and product lines. Recent announcements regarding investigational vaccines for seasonal influenza and respiratory syncytial virus signal a commitment to expanding its portfolio. However, the success of these initiatives will depend on regulatory approvals and market acceptance, which remain uncertain.
Investors should closely monitor Moderna's international expansion efforts, as highlighted by Bank of America. The potential for growth in global markets could offset domestic revenue declines, but execution will be key. Any setbacks in launching new products or entering new regions could further erode investor confidence. As the company navigates these challenges, its financial health will be under scrutiny, particularly regarding cash generation and operational efficiency. Keeping an eye on upcoming presentations and product developments will be crucial for understanding Moderna's trajectory in the coming months.
Red & Green Flags
This section distills all of the report's positives (green flags), negatives (red flags) and open questions (unknowns) into one place. The Overall view reflects a read of the evidence across the full report; it is not a simple tally of the lists below.
Green Flags
- Moderna has established itself as a leader in biotechnology, particularly in mRNA technology.
- The company has a strong liquidity position with cash and cash equivalents totaling $2.60 billion.
- Moderna's current ratio of 3.29 indicates it can cover short-term obligations.
- The cash conversion cycle has improved, reflecting better working capital management.
- Recent announcements about investigational vaccines for seasonal influenza and respiratory syncytial virus show commitment to expanding its portfolio.
- Bank of America highlighted international opportunities as a key growth driver for Moderna.
Red Flags
- Moderna reported a significant revenue decline from $3.20 billion in 2024 to $1.94 billion in 2025.
- The company has a negative earnings yield of -14.13%, raising concerns about profitability.
- Operating cash flow was -$1.87 billion, indicating ongoing challenges in cash generation.
- The reliance on COVID-19 vaccine revenues poses a significant operational risk as demand wanes.
- Days of payables outstanding have increased, suggesting longer payment times to suppliers, which could impact relationships.
- The price-to-earnings ratio of -7.08 and enterprise-value-to-EBITDA multiple of -7.62 reflect significant market uncertainty.
Unknowns
- The success of new vaccine initiatives depends on regulatory approvals and market acceptance, which remain uncertain.
- The impact of international expansion efforts on revenue growth is still to be determined.
- Future investor confidence hinges on Moderna's ability to restore profitability and operational efficiency.
6 green flags, 6 red flags, 3 unknowns.
Overall view: Bearish/Neutral.
Why this view:
- Moderna's revenue declined sharply from $3.20 billion in 2024 to $1.94 billion in 2025, raising sustainability concerns.
- The company reported an operating cash flow of -$1.87 billion, indicating significant cash generation challenges.
- Heavy reliance on COVID-19 vaccine revenues poses operational risks as pandemic demand wanes.
- Intense competition in the biotechnology sector complicates Moderna's ability to maintain growth without successful diversification.
- Negative earnings yield of -14.13% and no dividends may deter potential investors.
Action Checklist
Below are the next research steps a retail investor should consider based on this report.
Disclaimer
This Company Report is based on publicly available information and original research, and is provided for informational purposes only. It does not constitute financial, investment, or legal advice, nor an offer or solicitation to buy or sell any security. Readers should conduct their own due diligence and consult qualified advisors before making any investment decisions. Company performance can change rapidly and past results are not a guarantee of future outcomes. The author and publisher accept no responsibility for any actions taken based on this report.